Last reviewed · How we verify

Human Umbilical Cord Blood Plasma

Hexagon Therapies, LLC · Phase 1 active Biologic

Human Umbilical Cord Blood Plasma is a Biologic drug developed by Hexagon Therapies, LLC. It is currently in Phase 1 development.

At a glance

Generic nameHuman Umbilical Cord Blood Plasma
SponsorHexagon Therapies, LLC
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Human Umbilical Cord Blood Plasma

What is Human Umbilical Cord Blood Plasma?

Human Umbilical Cord Blood Plasma is a Biologic drug developed by Hexagon Therapies, LLC.

Who makes Human Umbilical Cord Blood Plasma?

Human Umbilical Cord Blood Plasma is developed by Hexagon Therapies, LLC (see full Hexagon Therapies, LLC pipeline at /company/hexagon-therapies-llc).

What development phase is Human Umbilical Cord Blood Plasma in?

Human Umbilical Cord Blood Plasma is in Phase 1.

Related